Global Reach Health – Page 10 – Global Reach Health

July 10, 2023

Other Announcements:
FDA Grants Leqembi Full Approval for Alzheimer’s Care

The Food and Drug Administration granted traditional (full) approval to Leqembi, the Alzheimer’s treatment jointly developed by Biogen and Eisai, on July 6th. In early June, external advisors to the FDA unanimously recommended Leqembi for full approval.

July 10, 2023

In Study, Almost Half of Obese Teens Were No Longer So After Taking Wegovy/Ozempic

By Denise Mann HealthDay Reporter

July 10, 2023 - The drugs Wegovy and Ozempic are all the rage for weight loss these days, and now a new study shows these injections may be game-changers for obese teenagers, too.

July 6, 2023

Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol SulfateInhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect

July 6, 2023 – Cipla Limited’s wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol

June 29, 2023

FDA Approves Roctavian (valoctocogene roxaparvovec-rvox) Gene Therapy for Adults with SevereHemophilia A

June 29, 2023 - BioMarin Pharmaceutical Inc., announced that the United States Food and Drug Administration (FDA) approved Roctavian^TM

June 28, 2023

FDA Approves Ngenla (somatrogon-ghla) Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

June 28, 2023 - Pfizer Inc. and OPKO Health Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Ngenla (somatrogon-ghla), a once-weekly

June 28, 2023

FDA Approves Lantidra (donislecel-jujn) Cellular Therapy to Treat Patients with Type 1 Diabetes

June 28, 2023 - The U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment

June 27, 2023

FDA Approves Rystiggo (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis

June 27, 2023 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, has announced Rystiggo (rozanolixizumab-noli) has been approved

June 23, 2023

FDA Approves Litfulo (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

June 23, 2023 - Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Litfulo (ritlecitinib), a once-daily oral treatment